Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
44 hedge funds and large institutions have $170M invested in Galera Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
27% more capital invested
Capital invested by funds: $134M → $170M (+$36.2M)
7% more funds holding
Funds holding: 41 → 44 (+3)
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$409K |
| 2 |
Millennium Management
New York
|
+$221K |
| 3 |
BlackRock
New York
|
+$202K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$176K |
| 5 |
Goldman Sachs
New York
|
+$167K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IM
Islet Management
New York
|
-$418K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$74.5K |
| 3 |
Renaissance Technologies
New York
|
-$71.2K |
| 4 |
Morgan Stanley
New York
|
-$23.9K |
| 5 |
State Street
Boston,
Massachusetts
|
-$21K |
GRTX Hedge Fund Activity: Q3 2020 in Review
44 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q3 2020, worth a combined $170M — up 27% from $134M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GRTX positions and 2 closed out — a net gain of 3 holders — while 7 added to existing stakes and 14 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $409K. The largest seller was Islet Management, exiting entirely with an estimated $418K sold.
- 44 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q3 2020, up from 41 in Q2 2020.
- Funds reported $170M of Galera Therapeutics, Inc. Common Stock stock for Q3 2020, up 27% quarter-over-quarter.
- 5 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q3 2020 and 2 closed out, a net change of +3 holders.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q3 2020 was VR Adviser, an estimated $409K added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q3 2020 was Islet Management, an estimated $418K sold.
Based on aggregated 13F filings for Q3 2020.